{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=11",
    "query": {
      "condition": "Melanoma, Skin",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 2054,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T04:37:36.618Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00304525",
      "title": "A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "RAF265",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2006-04",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304525"
    },
    {
      "nct_id": "NCT04967196",
      "title": "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lymph Node Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-16",
      "completion_date": "2024-04-17",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04967196"
    },
    {
      "nct_id": "NCT02889861",
      "title": "IMCgp100-401 Rollover Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "IMCgp100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-01-11",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889861"
    },
    {
      "nct_id": "NCT00273910",
      "title": "Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-Risk Melanoma"
      ],
      "interventions": [
        {
          "name": "gp100:209-217 (210M)",
          "type": "DRUG"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        },
        {
          "name": "Imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2006-01",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-10-19",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273910"
    },
    {
      "nct_id": "NCT04657991",
      "title": "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 257,
      "start_date": "2021-01-15",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 27,
      "location_summary": "Orlando, Florida • Fairway, Kansas • Overland Park, Kansas + 16 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04657991"
    },
    {
      "nct_id": "NCT06153238",
      "title": "A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GME751",
          "type": "DRUG"
        },
        {
          "name": "Keytruda - EU",
          "type": "DRUG"
        },
        {
          "name": "Keytruda - US",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 322,
      "start_date": "2024-05-15",
      "completion_date": "2026-05-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 3,
      "location_summary": "Orange, California • Clermont, Florida • Orange City, Florida",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06153238"
    },
    {
      "nct_id": "NCT01205815",
      "title": "Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Tissue and blood collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2010-06-03",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205815"
    },
    {
      "nct_id": "NCT00002860",
      "title": "SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "1996-11",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2012-01-13",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 124,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 81 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002860"
    },
    {
      "nct_id": "NCT02332668",
      "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Lymphoma",
        "Solid Tumor",
        "Classical Hodgkin Lymphoma",
        "Microsatellite-instability-high Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 370,
      "start_date": "2015-03-19",
      "completion_date": "2028-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02332668"
    },
    {
      "nct_id": "NCT01468818",
      "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Young Tumor Infiltrating Lymphocytes (TIL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-09",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-06-27",
      "last_synced_at": "2026-11-19T04:37:36.618Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01468818"
    }
  ]
}